Adipose-Derived Stromal Vascular Fraction Cells and Platelet-Rich Plasma: Basic and Clinical Implications for Tissue Engineering Therapies in Regenerative Surgery

2018 ◽  
pp. 107-122 ◽  
Author(s):  
Pietro Gentile ◽  
Valerio Cervelli
Keyword(s):  
Tissue Engineering ◽  
Platelet Rich Plasma ◽  
Stromal Vascular Fraction ◽  
Clinical Implications

scholarly journals Biocompatible chitosan–collagen–hydroxyapatite nanofibers coated with platelet-rich plasma for regenerative engineering of the rotator cuff of the shoulder

RSC Advances ◽  
2019 ◽  
Vol 9 (46) ◽  
pp. 27013-27020 ◽  
Author(s):  
Yi Tang ◽  
Hui Zhang ◽  
Qinghua Wei ◽  
Xu Tang ◽  
Wanqiang Zhuang
Keyword(s):  
Tissue Engineering ◽  
Rotator Cuff ◽  
Bone Tissue Engineering ◽  
Bone Tissue ◽  
Platelet Rich Plasma ◽  
Regenerative Engineering

Over the last few decades, extraordinary progress has been accomplished in the field of bone tissue engineering.

scholarly journals Adipose tissue derived stromal vascular fraction transplantation can recover spinal cord injury in mice

2016 ◽  
Vol 3 (04) ◽  
pp. 144 ◽  
Author(s):  
Hau Thi-My Lam ◽  
Minh Nguyen-Thu Tran ◽  
Khoa Anh Bui ◽  
Thao Thi-Thu Le ◽  
Khanh Hong-Thien Bui ◽  
...  
Keyword(s):  
Spinal Cord ◽  
Spinal Cord Injury ◽  
Adipose Tissue ◽  
Mouse Model ◽  
Platelet Rich Plasma ◽  
Stromal Vascular Fraction ◽  
Paracrine Factors ◽  
Diabetic Ulcer ◽  
Motor Test ◽  
Cord Injury

Introduction: Stem cell therapy is one of the most promising therapies for degenerative diseases and related injuries. Adipose tissue derived stem cells (ADSCs) exhibit some particular properties such as high production of paracrine factors. Indeed, ADSCs have been successfully used to treat diseases, including osteoarthritis, diabetic ulcer, etc. Methods: In this study, ADSCs were used to treat spinal cord injury (SCI) in a mouse model. Non-expanded ADSCs, from stromal vascular fractions (SVFs) isolated from both autologous and allogeneic adipose tissues, were injected into injured sites of mice at a specified dose. The SCI mouse model were generated by transection of spinal cord at vertebrae T8 - T10. After 1 week of transection, mice exhibiting completed SCI were divided into 4 groups: group 1 was control (mice without any treatment), group 2 was placebo (mice treated with platelet rich plasma (PRP)), group 3 was allogeneic SVF transplantation (mice treated with allogeneic SVFs), and group 4 was autologous SVF transplantation (mice treated with autologous SVFs). For the treatment groups, mice were transplanted with 20 µL of activated PRP or/and with 106 cells of SVF (allogeneic or autologous) into the injured position through laminectomy. The recovery of SCI was evaluated by locomotor test, sensory test and sensory-motor test at 5 weeks after transplantation. The histology of the spinal cord also was checked after 5 weeks. Results: The results showed that in all groups with PRP injected with or without SVFs, the inflammation was efficiently controlled. The glial scar as well as myelin defragmentation were clearly reduced. However, a significant improvement of BBB score was only recorded in mice transplanted with autologous SVFs. Conclusion: The results of our study show that autologous SVF transplantation in combination with PRP can be a promising therapy for SCI.

Fabrication and characterization of platelet-rich plasma scaffolds for tissue engineering applications

2017 ◽  
Vol 71 ◽  
pp. 372-380 ◽  
Author(s):  
Mahmoud Sadeghi-Ataabadi ◽  
Zohreh Mostafavi-pour ◽  
Zahra Vojdani ◽  
Mahsa Sani ◽  
Mona Latifi ◽  
...  
Keyword(s):  
Tissue Engineering ◽  
Platelet Rich Plasma ◽  
Engineering Applications ◽  
Fabrication And Characterization

scholarly journals Cell-secreted extracellular matrix, independent of cell source, promotes the osteogenic differentiation of human stromal vascular fraction

2018 ◽  
Vol 6 (24) ◽  
pp. 4104-4115 ◽  
Author(s):  
Jenna N. Harvestine ◽  
Hakan Orbay ◽  
Jonathan Y. Chen ◽  
David E. Sahar ◽  
J. Kent Leach
Keyword(s):  
Tissue Engineering ◽  
Extracellular Matrix ◽  
Bone Tissue Engineering ◽  
Osteogenic Differentiation ◽  
Bone Tissue ◽  
Stromal Vascular Fraction ◽  
Cell Source

Cell-secreted extracellular matrix potentiates osteogenic differentiation by stromal vascular fraction for bone tissue engineering.

scholarly journals Development of Autologous Platelet-Rich Plasma Mixed-Microfat as an Advanced Therapy Medicinal Product for Intra-Articular Injection of Radio-Carpal Osteoarthritis: From Validation Data to Preliminary Clinical Results

2019 ◽  
Vol 20 (5) ◽  
pp. 1111 ◽  
Author(s):  
Alice Mayoly ◽  
Aurélie Iniesta ◽  
Caroline Curvale ◽  
Najib Kachouh ◽  
Charlotte Jaloux ◽  
...  
Keyword(s):  
Medicinal Product ◽  
Platelet Rich Plasma ◽  
Stromal Vascular Fraction ◽  
Clinical Results ◽  
Advanced Therapy Medicinal Product ◽  
Validation Data ◽  
Painful Condition ◽  
Advanced Therapy ◽  
Functional Scores

Wrist osteoarthritis (OA) is one of the most common conditions encountered by hand surgeons with limited efficacy of non-surgical treatments. The purpose of this study is to describe the Platelet-Rich Plasma (PRP) mixed-microfat biological characteristics of an experimental Advanced Therapy Medicinal Product (ATMP) needed for clinical trial authorization and describe the clinical results obtained from our first three patients 12 months after treatment (NCT03164122). Biological characterization of microfat, PRP and mixture were analysed in vitro according to validated methods. Patients with stage four OA according to the Kellgren Lawrence classification, with failure to conservative treatment and a persistent daily painful condition >40 mm according to the visual analog scale (VAS) were treated. Microfat-PRP ATMP is a product with high platelet purity, conserved viability of stromal vascular fraction cells, chondrogenic differentiation capacity in vitro and high secretion of IL-1Ra anti-inflammatory cytokine. For patients, the only side effect was pain at the adipose tissue harvesting sites. Potential efficacy was observed with a pain decrease of over 50% (per VAS score) and the achievement of minimal clinically important differences for DASH and PRWE functional scores at one year in all three patients. Microfat-PRP ATMP presented a good safety profile after an injection in wrist OA. Efficacy trials are necessary to assess whether this innovative strategy could delay the necessity to perform non-conservative surgery.

scholarly journals Knee Osteoarthritis: A Review of Pathogenesis and State-Of-The-Art Non-Operative Therapeutic Considerations

Genes ◽  
2020 ◽  
Vol 11 (8) ◽  
pp. 854
Author(s):  
Dragan Primorac ◽  
Vilim Molnar ◽  
Eduard Rod ◽  
Željko Jeleč ◽  
Fabijan Čukelj ◽  
...  
Keyword(s):  
Knee Osteoarthritis ◽  
Platelet Rich Plasma ◽  
Treatment Options ◽  
Stromal Vascular Fraction ◽  
Disease Stage ◽  
Knee Oa ◽  
Marrow Mesenchymal Stem Cells ◽  
The Moment ◽  
And Function ◽  
Orthopedic Patients

Being the most common musculoskeletal progressive condition, osteoarthritis is an interesting target for research. It is estimated that the prevalence of knee osteoarthritis (OA) among adults 60 years of age or older is approximately 10% in men and 13% in women, making knee OA one of the leading causes of disability in elderly population. Today, we know that osteoarthritis is not a disease characterized by loss of cartilage due to mechanical loading only, but a condition that affects all of the tissues in the joint, causing detectable changes in tissue architecture, its metabolism and function. All of these changes are mediated by a complex and not yet fully researched interplay of proinflammatory and anti-inflammatory cytokines, chemokines, growth factors and adipokines, all of which can be measured in the serum, synovium and histological samples, potentially serving as biomarkers of disease stage and progression. Another key aspect of disease progression is the epigenome that regulates all the genetic expression through DNA methylation, histone modifications, and mRNA interference. A lot of work has been put into developing non-surgical treatment options to slow down the natural course of osteoarthritis to postpone, or maybe even replace extensive surgeries such as total knee arthroplasty. At the moment, biological treatments such as platelet-rich plasma, bone marrow mesenchymal stem cells and autologous microfragmented adipose tissue containing stromal vascular fraction are ordinarily used. Furthermore, the latter two mentioned cell-based treatment options seem to be the only methods so far that increase the quality of cartilage in osteoarthritis patients. Yet, in the future, gene therapy could potentially become an option for orthopedic patients. In the following review, we summarized all of the latest and most important research in basic sciences, pathogenesis, and non-operative treatment.

Sign in / Sign up

Export Citation Format

Share Document